First, we run through 4 recent FDA-approved expanded indications for HCC, small cell lung cancer, MDS-related anemia, and BRAF-v600e-mutated colorectal cancer.

Then, we review the evidence that warranted bevacizumab's FDA-approval for metastatic breast cancer way back in 2008 (E2100) and its subsequent labeled indication removal by the FDA (Avado & Ribbon-1).

Why talk about old news? Perhaps there's a lesson here as we consider using untested drugs...

E2100: https://www.nejm.org/doi/full/10.1056/nejmoa072113

Avado: https://www.ncbi.nlm.nih.gov/pubmed/20498403

Ribbon-1: https://www.ncbi.nlm.nih.gov/pubmed/21383283